Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine launch syndrome and related neurotoxicity in most cancers immunotherapy. Nat Rev Immunol. 2022;22(2):85–96.
Chowell D, Yoo SK, Valero C, Pastore A, Krishna C, Lee M, Hoen D, Shi H, Kelly DW, Patel N, Makarov V, Ma X, Vuong L, Sabio EY, Weiss Ok, Kuo F, Lenz TL, Samstein RM, Riaz N, Adusumilli PS, Balachandran VP, Plitas G, Ari Hakimi A, Abdel-Wahab O, Shoushtari AN, Postow MA, Motzer RJ, Ladanyi M, Zehir A, Berger MF, Gonen M, Morris LGT, Weinhold N, Chan T. A., Improved prediction of immune checkpoint blockade efficacy throughout a number of most cancers sorts. Nat Biotechnol. 2022;40(4):499–506.
Kubli SP, Berger T, Araujo DV, Siu LL, Mak TW. Past immune checkpoint blockade: rising immunological methods. Nat Rev Drug Discov. 2021;20(12):899–919.
Ribas A, Wolchok JD. Most cancers immunotherapy utilizing checkpoint blockade. Science. 2018;359(6382):1350–5.
Han HS, Jeong S, Kim H, Kim HD, Kim AR, Kwon M, Park SH, Woo CG, Kim HK, Lee KH, Search engine optimization SP, Kang HW, Kim WT, Kim WJ, Yun SJ, Shin EC. TOX-expressing terminally exhausted tumor-infiltrating CD8(+) T cells are reinvigorated by co-blockade of PD-1 and TIGIT in Bladder most cancers. Most cancers Lett. 2021;499:137–47.
McLane LM, Abdel-Hakeem MS, Wherry EJ. CD8 T cell exhaustion throughout persistent viral An infection and Most cancers. Annu Rev Immunol. 2019;37:457–95.
Arcia-Anaya D, Elliott T. STAT5A antagonizes TOX in CD8(+) T cell exhaustion. Nat Rev Immunol. 2023;23(2):73.
Chen C, Ni X, Jia S, Liang Y, Wu X, Kong D, Ding D. Massively evoking immunogenic cell dying by targeted mitochondrial oxidative stress utilizing an AIE Luminogen with a twisted molecular construction. Adv Mater 2019, 31 (52), e1904914.
Finlay D, Cantrell DA. Metabolism, migration and reminiscence in cytotoxic T cells. Nat Rev Immunol. 2011;11(2):109–17.
Chen SW, Zhu SQ, Pei X, Qiu BQ, Xiong D, Lengthy X, Lin Ok, Lu F, Xu JJ, Wu YB. Most cancers cell-derived exosomal circUSP7 induces CD8(+) T cell dysfunction and anti-PD1 resistance by regulating the miR-934/SHP2 axis in NSCLC. Mol Most cancers. 2021;20(1):144.
Kroy DC, Ciuffreda D, Cooperrider JH, Tomlinson M, Hauck GD, Aneja J, Berger C, Wolski D, Carrington M, Wherry EJ, Chung RT, Tanabe KK, Elias N, Freeman GJ, de Kruyff RH, Misdraji J, Kim AY, Lauer GM. Liver setting and HCV replication have an effect on human T-cell phenotype and expression of inhibitory receptors. Gastroenterology. 2014;146(2):550–61.
Wu Y, Ju Q, Jia Ok, Yu J, Shi H, Wu H, Jiang M. Correlation between intercourse and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors). Int J Most cancers. 2018;143(1):45–51.
Alfei F, Kanev Ok, Hofmann M, Wu M, Ghoneim HE, Roelli P, Utzschneider DT, von Hoesslin M, Cullen JG, Fan Y, Eisenberg V, Wohlleber D, Steiger Ok, Merkler D, Delorenzi M, Knolle PA, Cohen CJ, Thimme R, Youngblood B, Zehn D. TOX reinforces the phenotype and longevity of exhausted T cells in persistent viral An infection. Nature. 2019;571(7764):265–9.
Sekine T, Perez-Potti A, Nguyen S, Gorin JB, Wu VH, Gostick E, Llewellyn-Lacey S, Hammer Q, Falck-Jones S, Vangeti S, Yu M, Smed-Sorensen A, Gaballa A, Uhlin M, Sandberg JK, Brander C, Nowak P, Goepfert PA, Value DA, Betts MR, Buggert M. TOX is expressed by exhausted and polyfunctional human effector reminiscence CD8(+) T cells. Sci Immunol. 2020;5:49.
Wu P, Zhang H, Solar M, Mao S, He Q, Shi Y, Deng Y, Dong Z, Xu Q, Zhao C, Zhang W, Solar B. Manipulating offense and Protection Signaling to Combat Chilly tumors with Service-Free Nanoassembly of Fluorinated Prodrug and siRNA. Adv Mater. 2022;34(38):2203019.
Abdel-Hakeem MS, Manne S, Beltra JC, Stelekati E, Chen Z, Nzingha Ok, Ali MA, Johnson JL, Giles JR, Mathew D, Greenplate AR, Vahedi G, Wherry EJ. Epigenetic scarring of exhausted T cells hinders reminiscence differentiation upon eliminating persistent antigenic stimulation. Nat Immunol. 2021;22(8):1008–19.
Wang W, Saeed M, Zhou Y, Yang L, Wang D, Yu H. Non-viral gene supply for most cancers immunotherapy. J Gene Med 2019, 21 (7), e3092.
Huang X, Wu G, Liu C, Hua X, Tang Z, Xiao Y, Chen W, Zhou J, Kong N, Huang P, Shi J, Tao W. Intercalation-driven formation of siRNA nanogels for Most cancers Remedy. Nano Lett. 2021;21(22):9706–14.
Wu P, Yin S, Liu T, Ding D, Wang Ok. Constructing-block crosslinking micelles for enhancing mobile transfection of biocompatible polycations. Sci China Mater 2020.
Li Z, Wang Y, Shen Y, Qian C, Oupicky D, Solar M. Concentrating on pulmonary Tumor microenvironment with CXCR4-inhibiting nanocomplex to reinforce anti-PD-L1 immunotherapy. Sci Adv. 2020;6(20):eaaz9240.
Shen W, Wang Q, Shen Y, Gao X, Li L, Yan Y, Wang H, Cheng Y. Inexperienced Tea Catechin dramatically promotes RNAi mediated by low-molecular-weight polymers. ACS Cent Sci. 2018;4(10):1326–33.
Wu P, Zhang H, Yin Y, Solar M, Mao S, Chen H, Deng Y, Chen S, Li S, Solar B. Engineered EGCG-Containing Biomimetic nanoassemblies as efficient supply platform for enhanced Most cancers Remedy. Adv Sci. 2022;9(15):2105894.
Rawangkan A, Wongsirisin P, Namiki Ok, Iida Ok, Kobayashi Y, Shimizu Y, Fujiki H, Suganuma M. Inexperienced Tea Catechin is an alternate Immune checkpoint inhibitor that inhibits PD-L1 expression and lung Tumor progress. Molecules. 2018;23(8):2071.
Gao Z, Jia S, Ou H, Hong Y, Shan Ok, Kong X, Wang Z, Feng G, Ding D. An Activatable Close to-Infrared Afterglow Theranostic Prodrug with Self-sustainable magnification impact of immunogenic cell dying. Angew Chem Int Ed Engl 2022, 61 (40), e202209793.
Li J, Gao H, Liu R, Chen C, Zeng S, Liu Q, Ding D. Endoplasmic reticulum focused AIE bioprobe as a extremely environment friendly inducer of immunogenic cell dying. Sci China Chem. 2020;63(10):1428–34.
Wu P, Luo X, Wu H, Zhang Q, Dai Y, Solar M. Environment friendly and focused chemo-gene supply with self-assembled fluoro-nanoparticles for liver fibrosis remedy and recurrence. Biomaterials. 2020;261:120311.
Xiao YP, Zhang J, Liu YH, Huang Z, Wang B, Zhang YM, Yu XQ. Cross-linked polymers with fluorinated bridges for environment friendly gene supply. J Mater Chem B. 2017;5(43):8542–53.
Yang P, Peng Y, Feng Y, Xu Z, Feng P, Cao J, Chen Y, Chen X, Cao X, Yang Y, Jie J. Immune Cell-Derived Extracellular vesicles – New Methods in Most cancers Immunotherapy. Entrance Immunol. 2021;12:771551.
Lv J, Cheng Y. Fluoropolymers in biomedical purposes: state-of-the-art and future views. Chem Soc Rev. 2021;50(9):5435–67.
Wang M, Liu H, Li L, Cheng Y. A fluorinated dendrimer achieves wonderful gene transfection efficacy at extraordinarily low nitrogen to phosphorus ratios. Nat Commun. 2014;5:3053.
Xu J, Lv J, Zhuang Q, Yang Z, Cao Z, Xu L, Pei P, Wang C, Wu H, Dong Z, Chao Y, Wang C, Yang Ok, Peng R, Cheng Y, Liu Z. A common technique in direction of customized nanovaccines primarily based on fluoropolymers for post-surgical most cancers immunotherapy. Nat Nanotechnol. 2020;15(12):1043–52.
Ren F, Li Z, Li Ok, Zheng X, Shi J, Zhang C, Guo H, Tong B, Xi L, Cai Z, Dong Y. Donor technique for selling nonradiative decay to realize an environment friendly photothermal remedy for treating most cancers. Sci China Chem. 2021;64(9):1530–9.
Shao H, Cheng S, Yao M, Ji X, Zhong H, Wang D, Fan X, Li Q, Zhou J, Zhang Y, Peng F. A pH-response chemotherapy synergistic photothermal remedy for Tumor suppression and bone regeneration by mussel-inspired mg implant. Regen Biomater. 2021;8(6):rbab053.
Kamada T, Togashi Y, Tay C, Ha D, Sasaki A, Nakamura Y, Sato E, Fukuoka S, Tada Y, Tanaka A, Morikawa H, Kawazoe A, Kinoshita T, Shitara Ok, Sakaguchi S, Nishikawa H. PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of most cancers. Proc Natl Acad Sci U S A. 2019;116(20):9999–10008.
Yu X, Chen L, Liu J, Dai B, Xu G, Shen G, Luo Q, Zhang Z. Immune modulation of liver sinusoidal endothelial cells by melittin nanoparticles suppresses liver Metastasis. Nat Commun 2019, 10 (1).
Yu J, Inexperienced MD, Li S, Solar Y, Journey SN, Choi JE, Rizvi SM, Qin A, Waninger JJ, Lang X, Chopra Z, El Naqa I, Zhou J, Bian Y, Jiang L, Tezel A, Skvarce J, Achar RK, Sitto M, Rosen BS, Su F, Narayanan SP, Cao X, Wei S, Szeliga W, Vatan L, Mayo C, Morgan MA, Schonewolf CA, Cuneo Ok, Kryczek I, Ma VT, Lao CD, Lawrence TS, Ramnath N, Wen F, Chinnaiyan AM, Cieslik M, Alva A, Zou W. Liver Metastasis restrains immunotherapy efficacy through macrophage-mediated T cell elimination. Nat Med. 2021;27(1):152–64.
Tune J, Jia X, Ariga Ok. Strategies with Nanoarchitectonics for Small molecules and nanostructures to control residing cells. Small Strategies. 2020;4(10):2000500.
Li Q, Liu J, Fan H, Shi L, Deng Y, Zhao L, Xiang M, Xu Y, Jiang X, Wang G, Wang L, Wang Z. IDO-inhibitor potentiated immunogenic chemotherapy abolishes main Tumor progress and eradicates metastatic lesions by focusing on distinct compartments inside Tumor microenvironment. Biomaterials. 2021;269:120388.
Ni X, Zhang X, Duan X, Zheng HL, Xue XS, Ding D. Close to-Infrared Afterglow luminescent aggregation-Induced Emission dots with Ultrahigh Tumor-to-liver Sign ratio for promoted image-guided Most cancers Surgical procedure. Nano Lett. 2019;19(1):318–30.
Zhao Z, Chen C, Wu W, Wang F, Du L, Zhang X, Xiong Y, He X, Cai Y, Kwok RTK, Lam JWY, Gao X, Solar P, Phillips DL, Ding D, Tang BZ. Extremely environment friendly photothermal nanoagent achieved by harvesting power through excited-state intramolecular movement inside nanoparticles. Nat Commun. 2019;10(1):768.
Wu Q, Wang Q, Tang X, Xu R, Zhang L, Chen X, Xue Q, Wang Z, Shi R, Wang F, Ju F, Zhang B, Zhou YL. Correlation between sufferers’ age and most cancers immunotherapy efficacy. Oncoimmunology 2019, 8 (4), e1568810.